Abstract
Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Current Pharmaceutical Design
Title:QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Volume: 20 Issue: 27
Author(s): Filomena Martins, Cristina Ventura, Susana Santos and Miguel Viveiros
Affiliation:
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Abstract: Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Export Options
About this article
Cite this article as:
Martins Filomena, Ventura Cristina, Santos Susana and Viveiros Miguel, QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118164434
DOI https://dx.doi.org/10.2174/1381612819666131118164434 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The First Kinetic Enzymatic Resolution of Methyl Ester of C75
Letters in Organic Chemistry A Comparative Study to Explore the Effect of Different Compounds in Immune Proteins of Human Beings Against Tuberculosis: An In-silico Approach
Current Bioinformatics Withdrawal Notice: Highly Effective Synthesis of Dibromide of (+)-(1R, 2R)-and (-)-(1S, 2S)-1,2-diphenyl-1,2- ethylenediammonium (DPEN·2HBr) Assisted by Microwave
Current Green Chemistry The Role of IL-15 Signaling in the Induction of Innate Antiviral Responses
Current Signal Transduction Therapy Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety
Current Molecular Pharmacology Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Synthesis, Docking and Antidiabetic Activity of Some Newer Benzamide Derivatives as Potential Glucokinase Activators
Letters in Drug Design & Discovery Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Trends and Economic Stress: A Challenge to Universal Access to Antiretroviral Treatment in India
Current HIV Research Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Electrospray Ionisation - Mass Spectrometry (ESI-MS) and Liquid Chromatography -Electrospray Ionisation - Mass Spectrometry (LC-ESI-MS) of Selected Pharmaceuticals
Current Pharmaceutical Analysis Synthesis and Evaluation of Antimicrobial Activity of Thiazolidinone Derivatives
Letters in Drug Design & Discovery Advancement Towards Tin-based Anticancer Chemotherapeutics: Structural Modification and Computer Modeling Approach to Drug-Enzyme Interactions
Current Topics in Medicinal Chemistry Mutation and Evolution of Antibiotic Resistance: Antibiotics as Promoters of Antibiotic Resistance?
Current Drug Targets Benzothiazole-based Compounds in Antibacterial Drug Discovery
Current Medicinal Chemistry Anti-infective Potential of Manzamine Alkaloids - A Review
Medicinal Chemistry Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
Current Medicinal Chemistry Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Genotyping and Drug Susceptibility Patterns of <i>M. Tuberculosis</i> Isolated from HIV Seropositive Patients in Tehran Iran
Current HIV Research